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Background: AEB071, an orally available PKC inhibitor, prevents organ rejection after transplantation in rodents and man. 
Furthermore, pro-inflammatory cytokines and inflammatory processes are important mediators of transplanted organ 
rejection. We therefore examined whether single or combination therapies of AEB071 and/or tacrolimus affect cytokine 
profiles in a rat cardiac allograft model.
Methods: AEB071 (60 mg/kg twice a day) and tacrolimus (0.6 or 1.2 mg/kg once a day) were orally administered daily after 
cardiac transplantation. Interferon (IFN)-γ, interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-10, and tumor necrosis factor (TNF)-α levels 
in serum were subsequently measured 5 days after cardiac transplantation using a multiplex protein assay system.
Results: All cytokine levels were significantly depressed in cardiac transplanted rats treated with AEB071, whereas tacrolimus 
only reduced IFN-γ, IL-2, IL-4, IL-6, and IL-10 levels. When administered in combination, AEB071 and low- or high-dose 
tacrolimus had additive effects on IFN-γ, IL-4, IL-6, and TNF-α.
Conclusions: These results suggest that AEB071 inhibits T cell activation by blocking the production of proinflammatory 
cytokines, and that tacrolimus combined with AEB071 can effectively regulate inflammatory cytokines in the transplantation 
setting.
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Introduction
Several novel immunosuppressive agents that utilize 
different mechanisms from calcineurin inhibitor to sup-
press T cell activation have the potential to avoid neph-
rotoxicity(1). Protein kinase C (PKC) isoforms play key 
roles in the downstream signaling pathways of T cell 
receptor (signal 1) and CD28 (signal 2), and thus, tar-
geting these molecules may provide novel approaches 
that block early T cell activation(2).
AEB071 (sotrastaurin) is a new low molecular weight 
compound that blocks early T cell activation by se-
lectively inhibiting PKC(3). The PKC family contains 
12 isoforms, and each isoform plays a unique role in 
the regulation of cellular functions(4). However, only 
PKCα, β, and θ have been reported to participate 
significantly in T and B cell signaling(5). PKCα-deficient 
mice exhibit a Th1 defect and much reduced interfer-
on (IFN)-γ levels(6), and PKCβ knockout mice are 
immunodeficient due to reduced humoral and cellular 
responses(7). In one study, pretreatment of cardiac 
myocytes with either calphostin or PKCε inhibitory 
peptide prevented the serum-related redistribution of 
the PKCε isoform and inhibited the serum-related se-
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cretion of tumor necrosis factor (TNF)-α, interleukin 
(IL)-1β, IL-6, and IL-10 by cardiac myocytes(8). PKCθ 
is a specific isoform that can be translocated to the 
immunological synapse(9), and plays an important role 
in the activation of nuclear factor-κB, nuclear factor 
of activated T cells, and transcription factor activator 
protein-1, and in the production of IL-2 and develop-
ment of Th2 and Th17 immune responses in vivo(10). 
AEB071 selectively inhibits the classical (α, β) and 
novel (δ, ε, η, and θ) PKC isoforms(11), and bio-
chemical and pharmacological characterizations show 
that AEB071 inhibits IL-2 and IFN-γ, which is con-
sistent with the phenotypes observed in PKCα and PKC
θ single and double knockout mice(6).
In a previous study, we examined the effect of 
AEB071 on the prevention of acute rejection and on 
graft survival prolongation in a rat heart transplantation 
model(12). In the present study, we examined serum 
cytokine profiles in rats administered a single use of 
AEB071 and/or tacrolimus to characterize the anti-in-




Adult male, 8- to 9-week-old, inbred Brown-Norway 
rats (RT1n haplotype) and Lewis rats (RT11 haplotype) 
were used as donors and recipients, respectively. Rats 
were housed in a specific pathogen-free room in a 
temperature controlled animal care facility under a set 
light-dark diurnal cycle. Rats had free access to water 
and food and were allowed to adapt to the local envi-
ronment for at least one week prior to any procedure.
2) Experimental heart transplantation
Rat heterotopic abdominal heart transplantation was 
performed(12). Average cold ischemic time was less 
than 40 minutes. Graft function was assessed daily via 
abdominal palpation by a single investigator. Technical 
failure was assumed for rats that lost palpable con-
traction of the graft within 3 days post-operatively, and 
these animals were excluded from the analysis.
3) Administration of immunosuppressive agents and 
study groups
AEB071, provided by Novartis (Basel, Switzerland), 
was dissolved in polyethylene glycol 400 and distilled 
water for oral administration. Tacrolimus solution (5 
mg/mL) was obtained from CKD Pharmaceutical 
(Seoul, Korea) and diluted in distilled water for oral 
administration. All rats were treated by oral gavage us-
ing rat-feeding needles. Doses of immunosuppressive 
agents were adjusted for animal body weight on a dai-
ly basis.
Six groups of six animals per group (randomly as-
signed) were used in this study, as follows: the con-
trol group (animals received no treatment after trans-
plantation), the AEB071 group (60 mg/kg twice a 
day), the low-dose tacrolimus group (0.6 mg/kg once 
a day), the high-dose tacrolimus group (1.2 mg/kg 
once a day), the AEB071/low-dose tacrolimus group 
(AEB071 60 mg/kg twice a day, tacrolimus 0.6 mg/kg 
once a day), and the AEB071/high-dose tacrolimus 
group (AEB071 60 mg/kg twice a day, and tacrolimus 
1.2 mg/kg once a day) The data about graft survival 
and the pathologic effects of AEB071 and/or tacrolimus 
in a rat heterotopic heart transplantation model of these 
groups were in detail in our previous report(12,13).
4) Blood sampling and the quantification of serum 
cytokine levels
Blood samples were obtained from all six recipients 
per group on day 5 post-transplantation after confirm-
ing heart graft functioning. To determine the effects of 
AEB071 and/or tacrolimus on serum cytokine profile, 
we measured the serum levels of IL-1β, IL-2, IL-4, 
IL-6, IL-10, IFN-γ, and TNF-α. Blood samples were 
obtained from the retro-orbital plexus of recipients us-
ing microhematocrit tubes. Serum IL-1β, IL-2, IL-4, 
IL-6, IL-10, IFN-γ, and TNF-α levels were measured 
using MILLIPLEX MAP Rat Cytokine Kits (Millipore Co., 
St. Charles, MO, USA) and the Luminex 200 Multiplex 
Protein Analysis System (Luminex, Austin, TX, USA), 
according to the manufacturer's instructions. Serum 
was diluted 1:5 for assays, and all samples were run 
in duplicate. The detection limit for each cytokine was 
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Fig. 1. Serum levels of cytokines after AEB071 or tacrolimus monotherapies. The AEB071 60 mg monotherapy group had significantly
lower serum levels of all cytokines than the untreated controls and significantly lower interleukin (IL)-4 levels than tacrolimus at
0.6 mg daily. Furthermore, the AEB071 60 mg group had lower serum levels of IL-6 and tumor necrosis factor (TNF)-α than either the 
tacrolimus 0.6 or 1.2 mg groups. Data are presented as mean±standard errors. Abbreviations: Tac, tacrolimus; IFN-γ, interferon-gamma;
NS, not significant. aP＜0.05 compared with the untreated control group.
4.88 pg/mL.
5) Statistical analysis
Data are expressed as means±standard errors. 
One-way ANOVA with Bonferroni's post hoc analysis 
was used to compare groups. P-values were adjusted 
using Bonferroni's correction. Data were analyzed us-
ing SPSS for Windows ver. 14.0 (SPSS Inc., Chicago, 
IL, USA), and statistical significance was accepted for 
P＜0.05.
Results
The AEB071 60 mg monotherapy group showed sig-
nificant decreases in all serum cytokine levels versus 
the control group and a significant decrease in IL-4 
versus the tacrolimus 0.6 mg monotherapy group. 
AEB071 60 mg monotherapy decreased the serum lev-
els of IL-6 and TNF-α more so than tacrolimus at 0.6 
or 1.2 mg (Fig. 1).
Combination treatments (groups 4 and 6) decreased 
IFN-γ more than tacrolimus monotherapy (groups 3 and 
5), and low-dose tacrolimus (0.6 mg/kg once a day) 
plus AEB071 decreased IFN-γ more than high-dose ta-
crolimus (1.2 mg/kg once a day). However, AEB071 
plus low-dose tacrolimus did not significantly decrease 
serum IL-1β as compared with tacrolimus mono-
therapy group. However, serum IL-1β was sig-
nificantly decreased by AEB071 plus high-dose tacroli-
mus than by tacrolimus high-dose monotherapy (Fig. 
2B). Furthermore, serum IL-2 levels were lower in all 
treatment groups, except the low-dose tacrolimus 
group, than in the control group (Fig. 1). Low-dose 
tacrolimus plus AEB071 significantly decreased serum 
IL-2 levels more so than low and high-dose tacrolimus 
(Fig. 2C). All doses of tacrolimus and/or AEB071 
markedly decreased serum IL-4 and IL-6 as compared 
with the control, and AEB071 decreased serum IL-6 
and TNF-α more than tacrolimus at any dose (Fig. 
1). Low-dose tacrolimus and AEB071 significantly de-
creased serum IL-4, IL-6, and TNF-α levels versus 
high-dose tacrolimus (Fig. 2D, E, and G). Serum IL-10 
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Fig. 3. Heart allograft survival time in response to AEB071 mon-
otherapy or to tacrolimus/AEB701 combinatorial therapies with
different tacrolimus doses. AEB071/low dose tacrolimus (Tac) 
enhanced heart allograft survival more so than high dose Tac
monotherapy in the Brown-Norway-to-Lewis rat heterotopic 
cardiac transplant model. When AEB071 60 mg/kg twice a day
was administered in combination with either low-dose or 
high-dose tacrolimus allograft survivals were similar. Adapted
from Fig. 1 of reference [13]. Data are presented as mean surviv-
al times±standard errors. Abbreviation: NS, not significant.
Fig. 2. (A-G) Serum levels of cytokines after tacrolimus monotherapy and after tacrolimus/AEB071 60 mg combination therapy. Data
are presented as mean±standard errors. Abbreviations: IFN-γ, interferon-gamma; Tac, tacrolimus; IL, interleukin; NS, not significant;
TNF, tumor necrosis factor. aCharacters present comparisons between low-dose (0.6 mg) tacrolimus plus AEB071 60 mg and high-dose
(1.2 mg) tacrolimus.
levels were decreased in all treated groups, but no 
significant difference was observed between treatment 
groups. Tacrolimus had no effect on serum TNF-α, 
but AEB071 monotherapies and AEB071/tacrolimus 
combination therapies significantly decreased serum 
TNF-α levels (Fig. 2G). The serum levels of all cyto-
kines, except IL-1β and TNF-α, were significantly de-
creased by low-dose tacrolimus plus AEB071 as com-
pared with high-dose tacrolimus.
We previously reported survival times and pathologic 
changes for AEB071 monotherapy and AEB071/tacrolimus 
combination therapy(12,13). In the previous study, 
AEB071 monotherapy prolonged allograft mean survival 
time (MST) versus untreated controls. Also, AEB071 plus 
tacrolimus prolonged MST versus high-dose tacrolimus mon-
otherapy (Fig. 3). In terms of cardiac graft histology, AEB071 
combined with tacrolimus 0.6 mg/kg/day significantly de-
creased rejection grades as indicated by reduced in-
flammatory cell infiltration in grafts (data not shown).
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Discussion
AEB071 monotherapy and combination therapies, in-
volving a variety of immunosuppressive agents, pro-
long survival in the settings of rat heterotopic heart 
transplantation, rat islet transplantation, and cyn-
omolgus monkey renal allografts(3,14). We previously 
demonstrated that AEB071 prevents acute rejection and 
prolongs graft survival in a rat heart transplantation 
model(12,13). In the current study, we utilized the 
same model and added a combination therapy group 
to monitor levels of serum cytokines, including proin-
flammatory cytokines (IFN-γ, IL-1β, IL-2, IL-6, and TNF-
α) and anti-inflammatory cytokines (IL-4 and IL-10), in 
rats treated with AEB071 and/or tacrolimus after re-
ceiving an cardiac allograft. We found AEB071 effec-
tively reduced serum cytokine levels, and that its po-
tency was similar to or greater than that of tacrolimus.
In the current study, we did not determine lympho-
cyte proportions or cytokine levels in graft tissues or 
draining lymph nodes. However, serum cytokines are 
implicated in the activation and regulation of Th1 and 
Th2 subsets of T cells. Th1 cells, which produce IL-2 
and IFN-γ, are involved in the cellular immune re-
sponse mediated by cytotoxic cells, macrophages, and 
natural killer cells(15,16). In contrast, Th2 cells pro-
duce IL-4, IL-5, IL-6, and IL-10, all of which predom-
inantly stimulate antibody-mediated humoral immune 
response(17). In particular, it has been reported that 
serum cytokines are involved in acute rejection after 
kidney transplantation(18).
In the present study, AEB071 monotherapy suppressed 
IL-1β and TNF-α levels more effectively than low or 
high dose tacrolimus monotherapy. In addition, AEB071 
decreased IL-4 more so than low-dose tacrolimus. IL-4 
activates B cells in addition to acting as an anti-in-
flammatory or counter-regulatory cytokine with IL-10 
and IL-13. Furthermore, IL-4 inhibits the secretion of 
pro-inflammatory cytokines by macrophages, but pro-
motes the growth and differentiation of B cells and di-
rects the differentiation of CD4＋ T cells into Th2 
cells(19,20). These findings imply that AEB071 might 
exert its immunosuppressive effects by inhibiting the 
differentiations of B and T cells. TNF-α has important 
roles both as an apoptosis initiator and an in-
flammation mediator(21), and can promote nearly all 
types of humoral and cellular immune responses regu-
lated by IL-1(22). In addition, TNF-α has been re-
ported to be a marker of acute rejection after kidney 
transplantation(23).
The main limitation of this study was that no lower 
dosages of AEB071 were used and compared with ta-
crolimus combinations, and thus, we could not explore 
synergism between tacrolimus and lower doses of AEB071. 
Furthermore, we did not monitor serum cytokine changes 
after transplantation, and we did not evaluate changes 
in B and T lymphocytes numbers in grafts or lymph 
nodes. Additional studies are warranted.
Nevertheless, low-dose tacrolimus combined with 
AEB071 more effectively decreased serum inflammatory 
cytokine levels (IFN-γ, IL-4, IL-6, and TNF-α) than 
high-dose tacrolimus. Based on the finding of this and 
our previous studies(12,13), we suggest that the AEB071/ 
tacrolimus combination is more potent than tacrolimus 
alone.
Conclusion
Summarizing, this study shows that AEB071 has unique 
anti-inflammatory activities. In particular, it more effec-
tively suppressed the productions of IL-1β and TNF-
α than tacrolimus. Furthermore, our findings show 
that AEB071 blocks T cell activation and proin-
flammatory cytokine production after solid organ trans-
plantation, and suggest that the anti-inflammatory ef-
fects of the tacrolimus/AEB071 combination be consid-
ered in a clinical setting.
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